

Date-15<sup>th</sup> April, 2023

The Manager-Listing  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai-400001

The Manager- Listing  
National Stock Exchange of India Ltd.,  
Exchange Plaza, Bandra-Kurla Complex  
Bandra (E)  
Mumbai-400051

BSE Code-537291

NSE Code-NATHBIOGEN

Sub: Intimation of Board Meeting to consider Audited Financial Results of the Company for the 4<sup>th</sup> quarter and financial year ended 31<sup>st</sup> March 2023 and to consider recommendation of Dividend for the year 2022-23, if any.

Ref: Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 29 and 33 of the Listing Regulations 2015, Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Saturday, 22<sup>nd</sup> April 2023 to approve the following.

1. To consider, approve and take on record Audited Financial Results (Standalone and Consolidated) of the Company for the 4<sup>th</sup> quarter and year ended 31<sup>st</sup> March 2023.
2. To consider recommendation of Dividend for the year 2022-23, if any subject to Approval of shareholders in ensuing AGM.
3. To recommend Re-appointment of Mr. Satish Kagliwal, as Managing Director of the Company.
4. To decide the date of Annual General Meeting of the Company.
5. Any other business with the permission of board.

The Company has already closed its "Trading Window" under the Code of Conduct for prevention of Insider Trading from 31<sup>st</sup> March 2023 and it will re-open on 24<sup>th</sup> April 2023.

You are requested to take note of the above.

Thanking You.

Yours faithfully,  
For Nath Bio-Genes (India) Limited,

Devinder Khurana  
Chief Financial Officer